Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | TDP2 | O95551 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5113355 | 0.83 | ALDH1A1 (0.39) | ALDH1A1LMNAHPGDKDM4EBCL2 | |
| SCHEMBL7109725 | 0.81 | ALDH1A1 (0.58) | ALDH1A1LMNAHPGDKDM4EBCL2 | |
| SCHEMBL14098075 | 0.80 | ALDH1A1 (0.36) | ALDH1A1LMNAHPGDKDM4EBCL2 | |
| SCHEMBL14138452 | 0.80 | ALDH1A1 (0.36) | ALDH1A1LMNAHPGDKDM4EBCL2 | |
| SCHEMBL14098170 | 0.80 | ESR1 (0.43) | ALDH1A1LMNAHPGDKDM4EBCL2 | |
| SCHEMBL14098169 | 0.79 | ALDH1A1 (0.39) | ALDH1A1LMNAHPGDKDM4EBCL2 | |
| SCHEMBL14098162 | 0.76 | ERN1 (0.40) | ALDH1A1LMNAESR1ESR2 | |
| SCHEMBL14098177 | 0.76 | ALOX5 (0.40) | ALDH1A1LMNAHPGDESR1ESR2 | |
| SCHEMBL14098171 | 0.75 | ALDH1A1 (0.41) | ALDH1A1LMNAHPGDKDM4EBCL2 | |
| SCHEMBL5113545 | 0.75 | TDP2 (0.41) | ALDH1A1LMNAHPGDKDM4EBCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410997-B2 | Tricyclic fused heterocycle compounds, process for preparing the same and use thereof | NIPPON SULSAN KAISHA, LTD. (JP) | 2008-08-12 | — | — | US | disclosed |
| US-7410997-B2 | Tricyclic fused heterocycle compounds, process for preparing the same and use thereof | NIPPON SULSAN KAISHA, LTD. (JP) | 2008-08-12 | — | — | US | disclosed |
| US-7410997-B2 | Tricyclic fused heterocycle compounds, process for preparing the same and use thereof | NIPPON SULSAN KAISHA, LTD. (JP) | 2008-08-12 | — | — | US | disclosed |
| EP-1182200-B1 | TRICYCLIC FUSED HETEROCYCLE COMPOUNDS, PROCESS FOR PREPARING THE SAME AND USE THEREOF | NIPPON SUISAN KAISHA LTD (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20040127713-A1 | Tricyclic fused heterocycle compounds, process for preparing the same and use thereof | NIPPON SUISAN KAISHA, LTD. | 2004-07-01 | — | — | US | disclosed |
| US-6700013-B2 | O-BROMOPHENYLACETIC ACID DERIVATIVE CHEMICAL INTERMEDIATE; SMOOTH MUSCLE RELAXANTS, ANTIINFLAMMATORY AGENTS; RESPIRATORY SYSTEM DISORDERS | NIPPON SUISAN KAISHA, LTD. (JP) | 2004-03-02 | — | — | US | disclosed |
| US-20030220360-A1 | Tricyclic fused heterocycle compounds, process for preparing the same and use thereof | NIPPON SUISAN KAISHA, LTD., A JAPAN CORPORATION | 2003-11-27 | — | — | US | disclosed |
| US-6602898-B1 | Tricyclic fused heterocycle compounds, process for preparing the same and use thereof | NIPPON SUISAN KAISHA, LTD. (JP) | 2003-08-05 | — | — | US | disclosed |
| EP-1182200-A9 | TRICYCLIC FUSED HETEROCYCLE COMPOUNDS, PROCESS FOR PREPARING THE SAME AND USE THEREOF | Nippon Suisan Kaisha, Ltd. (JP) | 2002-05-22 | — | — | EP | disclosed |
| EP-1182200-A1 | TRICYCLIC FUSED HETEROCYCLE COMPOUNDS, PROCESS FOR PREPARING THE SAME AND USE THEREOF | Nippon Suisan Kaisha, Ltd. (JP) | 2002-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220360-A1 | Tricyclic fused heterocycle compounds, process for preparing the same and use thereof | HRH2, HRH1, HRH4 | ALDH1A1 899/4885LMNA 1326/4885HPGD 540/4885 |
| US-20040127713-A1 | Tricyclic fused heterocycle compounds, process for preparing the same and use thereof | HRH2, HRH1, HRH4 | ALDH1A1 899/4885LMNA 1326/4885HPGD 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.